Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-08-19 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于2024年度“提质增效重回报”专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度评估报告" (Half-Year Assessment Report) for the year 2024, issued by 科兴生物制药股份有限公司. It contains detailed operational and financial performance data for the first half of 2024, including revenue, profit figures, business strategy, R&D progress, governance updates, investor relations activities, and share repurchase information. The length is over 5,000 characters and it provides substantive financial data and management discussion for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a comprehensive report covering half-year performance and outlook. H1 2024
2024-08-19 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, core technologies, R&D progress, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes actual financial statements and substantive financial data for the first half of 2024. The presence of management discussion and analysis and detailed financial metrics confirms it is a comprehensive interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-19 Chinese
关于对山东证监局行政监管措施决定书的整改报告的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding its rectification report in response to administrative regulatory measures issued by the Shandong Securities Regulatory Bureau. It details the company's corrective actions related to prior disclosure inaccuracies, voluntary disclosure continuity, and improper use of raised funds. The document references prior announcements and regulatory decisions but does not contain financial statements or comprehensive financial data itself. It is a regulatory compliance and corrective action announcement rather than a full audit report or annual report. The document length is relatively short (3332 characters), and it primarily serves to inform about the rectification measures taken following regulatory findings. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-19 Chinese
第二届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 科兴生物制药股份有限公司 on August 19, 2024. It details the approval of the company's 2024 semi-annual report and related documents, but does not contain the report itself. Instead, it references that the actual semi-annual report and other related reports are disclosed separately on the Shanghai Stock Exchange website. The document also includes approvals of other board matters such as fund usage reports, action plan evaluations, termination of related party agreements, and regulatory remediation reports. The document length is 2178 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of board meeting resolutions and report approvals, not the report itself. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-08-19 Chinese
2024年半年度募集资金存放及实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 科兴生物制药股份有限公司 regarding the management and actual use of funds raised in the first half of 2024. It includes specifics on the amount of funds raised, usage, storage, investment projects, and compliance with regulatory requirements. The document references regulatory guidelines related to the management of raised funds and includes financial figures and project progress updates. It is not an announcement of a report but the report itself, containing substantive financial data and analysis about the use of capital raised through fundraising activities. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (7496 characters) supports it being a full report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2024-08-19 Chinese
第二届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding several agenda items including approval of the 2024 half-year report and its summary, a special report on the use of raised funds, termination of related party transactions, and a regulatory compliance report. The document references the half-year report and other detailed disclosures published on the stock exchange website but does not itself contain financial statements or substantive financial data. The document is relatively short (1602 characters) and serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-08-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.